ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024
Incorporating Supramaximal Resection into Survival Stratification of IDH-wildtype Glioblastoma: A Refined Multi-institutional Recursive Partitioning Analysis.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic revalidation of RANO categories for extent of resection in glioblastoma: a reconstruction of individual patient data.Journal of neuro-oncology · 2025Pooled it
- Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Patient-derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones.Brain pathology (Zurich, Switzerland) · 2026Article
- Circulating Placental Growth Factor as a Prognostic Biomarker in High-Risk Glioblastoma Patients.Biomedicines · 2026Article
- Higher cerebral metabolic rate of oxygen derived from dynamic susceptibility contrast MRI is an independent predictor of poor survival in IDH-wildtype glioblastoma.Neuroradiology · 2026Article
- Predicting molecular types of adult-type diffuse gliomas based on MRI reports with large language models.European radiology · 2026Article
- Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study.Journal of neuro-oncology · 2026Article
- Surgical decision making in the era of supramarginal glioma resections: a current perspective and narrative review.CNS oncology · 2025Review
- GLIMMER: an interim subgroup analysis from an ongoing prospective study evaluating hyperspectral imaging for MGMT promoter methylation in gliomas.Journal of neuro-oncology · 2025Observational
- Tumor oxygenation imaging biomarkers using dynamic susceptibility contrast imaging for prediction of IDH mutation status in adult-type diffuse gliomas.European radiology · 2025Article
- Molecular-based decision-making in glioblastoma surgery: When to aim for supramaximal resection.Neuro-oncology · 2025Review
- Repeat Resection for Recurrent Glioblastoma in the WHO 2021 Era: A Longitudinal Matched Case-Control Study.Brain sciences · 2025Article
- A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part II-Essential Information on Post-Treatment Imaging.Korean journal of radiology · 2025Review
- A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging.Korean journal of radiology · 2025Review
- The role of Lobectomy in Glioblastoma management: A Retrospective series.Brain & spine · 2025Article
- Population-based validation of the RANO categories for extent of resection in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
purposeTo propose a novel recursive partitioning analysis (RPA) classification model in patients with IDH-wildtype glioblastomas that incorporates the recently expanded conception of the extent of resection (EOR) in terms of both supramaximal and total resections. EXPERIMENTAL
designThis multicenter cohort study included a developmental cohort of 622 patients with IDH-wildtype glioblastomas from a single institution (Severance Hospital) and validation cohorts of 536 patients from three institutions (Seoul National University Hospital, Asan Medical Center, and Heidelberg University Hospital). All patients completed standard treatment including concurrent chemoradiotherapy and underwent testing to determine their IDH mutation and MGMTp methylation status. EORs were categorized into either supramaximal, total, or non-total resections. A novel RPA model was then developed and compared with a previous Radiation Therapy Oncology Group (RTOG) RPA model.
resultsIn the developmental cohort, the RPA model included age, MGMTp methylation status, Karnofsky performance status, and EOR. Younger patients with MGMTp methylation and supramaximal resections showed a more favorable prognosis [class I: median overall survival (OS) 57.3 months], whereas low-performing patients with non-total resections and without MGMTp methylation showed the worst prognosis (class IV: median OS 14.3 months). The prognostic significance of the RPA was subsequently confirmed in the validation cohorts, which revealed a greater separation between prognostic classes for all cohorts compared with the previous RTOG RPA model.
conclusionsThe proposed RPA model highlights the impact of supramaximal versus total resections and incorporates clinical and molecular factors into survival stratification. The RPA model may improve the accuracy of assessing prognostic groups. See related commentary by Karschnia et al., p. 4811.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.